1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The neoantigen cancer vaccine market presents transformative potential in oncology, offering a personalized approach to immune activation for cancer treatment. Senior decision-makers face a dynamic sector driven by rapid innovation, regulatory evolution, and shifting supply chain landscapes.
Market Snapshot: Neoantigen Cancer Vaccine Market
The Neoantigen Cancer Vaccine Market grew from USD 378.66 million in 2024 to USD 434.55 million in 2025. It is expected to continue growing at a CAGR of 15.01%, reaching USD 876.78 million by 2030.
Scope & Segmentation
- Neoantigen Types: Personalized neoantigens, including immune escape and somatic mutations; shared neoantigens, encompassing affinity peptides and common tumor mutations.
- Therapeutic Targets: Immune checkpoint blockade methods including CTLA-4 and PD-1 inhibitors; tumor neoantigens, both mutated and non-mutated variations.
- Vaccine Platforms: Cell-based (dendritic cell and T-cell vaccines), DNA-based (circular and plasmid DNA vaccines), peptide-based (long and synthetic peptides), and RNA-based (mRNA and next-generation RNA platforms).
- Administration Routes: Intradermal, intravenous, oral, and subcutaneous methods tailored to clinical needs.
- End Users: Cancer treatment centers, hospitals, and research institutes actively driving adoption and innovation.
- Regional Focus: Americas, Europe/Middle East/Africa, and Asia-Pacific segmented by country-level analysis, including leading and emerging markets.
- Key Industry Players: Major companies such as Agenus Inc., AstraZeneca PLC, BioNTech SE, Moderna, Inc., Gilead Sciences, Inc., CureVac N.V., and other innovators.
Key Takeaways for Decision-Makers
- Neoantigen vaccines harness individualized tumor profiles, enabling precise targeting and minimizing harm to healthy cells—a pivotal advantage over traditional immunotherapies.
- Next-generation sequencing and bioinformatics breakthroughs have accelerated target identification and advanced clinical progress across diverse tumor types.
- Collaborative partnerships between biotech firms, large pharmaceutical players, and contract manufacturing organizations are streamlining late-stage trials and scaling production capacity.
- Adaptive regulatory frameworks are emerging globally, offering pathways for expedited approval and real-world data integration, enhancing the speed and safety of market entry.
- Construction of modular production platforms supports customized manufacturing for both personalized and shared vaccine constructs, addressing the demands of precision oncology.
- Diversification of supply sources and near-shoring strategies are actively pursued to protect against supply chain disruptions and manage upstream input volatility.
Tariff Impact: Assessing US Tariff Influence
In 2025, new US tariffs on imported biopharmaceutical materials, including synthetic peptides, lipids, and nucleic acids, are reshaping cost structures for neoantigen vaccine producers. These policy changes have led manufacturers to renegotiate supplier agreements, explore domestic and near-shore sourcing, and invest in vertical integration. Industry collaborations are intensifying with trade associations and regulators to mitigate logistical challenges, enhance customs processes, and sustain production continuity for critical therapies.
Methodology & Data Sources
This report utilizes a multi-tiered approach, integrating expert interviews, quantitative datasets from proprietary and public sources, and secondary research from peer-reviewed literature, regulatory filings, and financial reports. Triangulation processes and expert panel reviews validate emerging trends and ensure accuracy.
Why This Report Matters
- Enables senior leaders to anticipate technological and regulatory shifts, identify new value opportunities, and guide strategic investments for sustainable growth.
- Delivers actionable segmentation insights and regional dynamics critical for prioritizing market entry and partnership strategies.
- Supports long-term planning by providing clarity regarding supply chain resilience, evolving reimbursement environments, and innovation drivers.
Conclusion
As the neoantigen cancer vaccine market evolves, stakeholders must align technical innovation, adaptive supply strategies, and regulatory engagement. Harnessing these market shifts supports impactful, patient-centered cancer immunotherapy advancements.
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates.
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of cancer diseases compelling robust research in personalized cancer vaccine solutions
5.1.1.2. Increasing public awareness about the benefits of personalized and preventive cancer treatments
5.1.1.3. Supportive government policies and funding for cancer research and development initiatives
5.1.2. Restraints
5.1.2.1. Concerns associated with significant side effects of neoantigen cancer vaccines
5.1.3. Opportunities
5.1.3.1. Strategic collaborations among biotech companies accelerating advancements in neoantigen vaccine research
5.1.3.2. Innovative technological advancements boosting the potential applications of neoantigen cancer vaccines
5.1.4. Challenges
5.1.4.1. Stringent regulatory environments and compliance for personalized vaccine approval
5.2. Market Segmentation Analysis
5.2.1. Neoantigen Type: Increasing need for personalized neoantigen cancer vaccines to target unique mutations specific to an individual’s tumor
5.2.2. End User: Expanding utilization of neoantigen vaccines by cancer treatment centers for personalized treatment efficacy
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
5.1.1. Drivers
5.1.1.1. Growing prevalence of cancer diseases compelling robust research in personalized cancer vaccine solutions
5.1.1.2. Increasing public awareness about the benefits of personalized and preventive cancer treatments
5.1.1.3. Supportive government policies and funding for cancer research and development initiatives
5.1.2. Restraints
5.1.2.1. Concerns associated with significant side effects of neoantigen cancer vaccines
5.1.3. Opportunities
5.1.3.1. Strategic collaborations among biotech companies accelerating advancements in neoantigen vaccine research
5.1.3.2. Innovative technological advancements boosting the potential applications of neoantigen cancer vaccines
5.1.4. Challenges
5.1.4.1. Stringent regulatory environments and compliance for personalized vaccine approval
5.2. Market Segmentation Analysis
5.2.1. Neoantigen Type: Increasing need for personalized neoantigen cancer vaccines to target unique mutations specific to an individual’s tumor
5.2.2. End User: Expanding utilization of neoantigen vaccines by cancer treatment centers for personalized treatment efficacy
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Neoantigen Cancer Vaccine Market, by Neoantigen Type
6.1. Introduction
6.2. Personalized Neoantigens
6.2.1. Immune Escape Mutations
6.2.2. Somatic Mutations
6.3. Shared Neoantigens
6.3.1. Affinity Peptides
6.3.2. Common Tumor Mutations
6.2. Personalized Neoantigens
6.2.1. Immune Escape Mutations
6.2.2. Somatic Mutations
6.3. Shared Neoantigens
6.3.1. Affinity Peptides
6.3.2. Common Tumor Mutations
7. Neoantigen Cancer Vaccine Market, by Therapeutic Target
7.1. Introduction
7.2. Immune Checkpoint Blockade
7.2.1. CTLA-4 Inhibitors
7.2.2. PD-1 Inhibitors
7.3. Tumor Neoantigens
7.3.1. Mutated Neoantigens
7.3.2. Non-Mutated Neoantigens
7.2. Immune Checkpoint Blockade
7.2.1. CTLA-4 Inhibitors
7.2.2. PD-1 Inhibitors
7.3. Tumor Neoantigens
7.3.1. Mutated Neoantigens
7.3.2. Non-Mutated Neoantigens
8. Neoantigen Cancer Vaccine Market, by Vaccine Platform
8.1. Introduction
8.2. Cell-Based Vaccines
8.2.1. Dendritic Cell Vaccines
8.2.2. T-Cell Vaccines
8.3. DNA-Based Vaccines
8.3.1. Circular DNA Platforms
8.3.2. Plasmid DNA Vaccines
8.4. Peptide-Based Vaccines
8.4.1. Long Peptides
8.4.2. Synthetic Peptides
8.5. RNA-Based Vaccines
8.5.1. mRNA Vaccines
8.5.2. Next-Gen RNA Platforms
8.2. Cell-Based Vaccines
8.2.1. Dendritic Cell Vaccines
8.2.2. T-Cell Vaccines
8.3. DNA-Based Vaccines
8.3.1. Circular DNA Platforms
8.3.2. Plasmid DNA Vaccines
8.4. Peptide-Based Vaccines
8.4.1. Long Peptides
8.4.2. Synthetic Peptides
8.5. RNA-Based Vaccines
8.5.1. mRNA Vaccines
8.5.2. Next-Gen RNA Platforms
9. Neoantigen Cancer Vaccine Market, by Administration Route
9.1. Introduction
9.2. Intradermal
9.3. Intravenous
9.4. Oral
9.5. Subcutaneous
9.2. Intradermal
9.3. Intravenous
9.4. Oral
9.5. Subcutaneous
10. Neoantigen Cancer Vaccine Market, by End User
10.1. Introduction
10.2. Cancer Treatment Centers
10.3. Hospitals
10.4. Research Institutes
10.2. Cancer Treatment Centers
10.3. Hospitals
10.4. Research Institutes
11. Americas Neoantigen Cancer Vaccine Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Neoantigen Cancer Vaccine Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Neoantigen Cancer Vaccine Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Scenario Analysis
14.3.1. Everest Medicines Initiated personalized mRNA cancer vaccines with EVM16 clinical trial for neoantigen targeting
14.3.2. Achilles Therapeutics and Arcturus Therapeutics to collaborate on next-generation personalized mRNA cancer vaccine research
14.3.3. Transgene and NEC expand collaboration to advance TG4050 neoantigen cancer vaccine into Phase I/II trial
14.4. Strategy Analysis & Recommendation
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Scenario Analysis
14.3.1. Everest Medicines Initiated personalized mRNA cancer vaccines with EVM16 clinical trial for neoantigen targeting
14.3.2. Achilles Therapeutics and Arcturus Therapeutics to collaborate on next-generation personalized mRNA cancer vaccine research
14.3.3. Transgene and NEC expand collaboration to advance TG4050 neoantigen cancer vaccine into Phase I/II trial
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. NEOANTIGEN CANCER VACCINE MARKET MULTI-CURRENCY
FIGURE 2. NEOANTIGEN CANCER VACCINE MARKET MULTI-LANGUAGE
FIGURE 3. NEOANTIGEN CANCER VACCINE MARKET RESEARCH PROCESS
FIGURE 4. NEOANTIGEN CANCER VACCINE MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2024 VS 2030 (%)
FIGURE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2024 VS 2030 (%)
FIGURE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2024 VS 2030 (%)
FIGURE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 15. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 17. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 19. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 21. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 23. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 26. NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 27. NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 2. NEOANTIGEN CANCER VACCINE MARKET MULTI-LANGUAGE
FIGURE 3. NEOANTIGEN CANCER VACCINE MARKET RESEARCH PROCESS
FIGURE 4. NEOANTIGEN CANCER VACCINE MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2024 VS 2030 (%)
FIGURE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2024 VS 2030 (%)
FIGURE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2024 VS 2030 (%)
FIGURE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 15. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 17. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 19. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 21. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 23. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 26. NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 27. NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. NEOANTIGEN CANCER VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. NEOANTIGEN CANCER VACCINE MARKET DYNAMICS
TABLE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 92. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 93. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 94. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 95. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 96. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 97. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 98. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 99. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 100. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 101. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 102. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 103. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 105. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 106. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 107. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 108. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 109. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 110. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 111. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 112. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 113. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 114. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 115. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 116. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 150. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 151. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 153. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 155. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 157. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 159. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 160. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 161. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 162. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 163. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 164. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 165. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 166. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 167. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 168. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 169. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 170. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 172. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 173. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 174. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 175. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 176. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 177. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 178. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 179. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 180. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 181. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 182. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 183. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 185. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 186. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 187. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 188. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 189. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 190. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 191. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 192. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 193. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 194. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 195. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 196. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 198. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 199. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 200. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 201. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 202. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 203. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 204. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 205. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 206. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 207. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 208. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 209. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 211. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 212. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 213. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 214. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 215. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 216. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 217. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 218. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 219. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 220. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 221. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 222. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 224. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 225. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 226. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 227. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 228. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 229. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 230. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 231. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 232. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 233. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 234. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 235. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 237. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 238. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 239. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 240. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 241. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 242. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 243. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 244. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 245. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 246. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 247. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 248. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 250. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 251. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 252. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 253. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 254. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 255. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 256. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 257. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 258. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 259. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 260. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 261. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 263. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 264. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 265. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 266. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 267. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 268. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 269. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 270. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 271. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 272. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 273. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 274. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 276. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 277. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 278. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 279. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 280. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 281. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 282. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 283. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 284. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 285. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 286. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 287. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 289. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 290. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 291. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 292. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 293. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 294. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 295. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 296. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 297. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 298. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 299. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 300. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 302. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 303. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 304. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 305. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 306. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 307. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 308. EUROPE, MIDDLE EAST & AFRICA NE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. NEOANTIGEN CANCER VACCINE MARKET DYNAMICS
TABLE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 92. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 93. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 94. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 95. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 96. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 97. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 98. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 99. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 100. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 101. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 102. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 103. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 105. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 106. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 107. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 108. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 109. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 110. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 111. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 112. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 113. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 114. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 115. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 116. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 150. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 151. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 153. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 155. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 157. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 159. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 160. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 161. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 162. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 163. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 164. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 165. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 166. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 167. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 168. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 169. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 170. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 172. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 173. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 174. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 175. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 176. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 177. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 178. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 179. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 180. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 181. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 182. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 183. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 185. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 186. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 187. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 188. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 189. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 190. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 191. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 192. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 193. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 194. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 195. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 196. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 198. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 199. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 200. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 201. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 202. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 203. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 204. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 205. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 206. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 207. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 208. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 209. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 211. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 212. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 213. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 214. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 215. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 216. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 217. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 218. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 219. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 220. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 221. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 222. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 224. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 225. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 226. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 227. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 228. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 229. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 230. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 231. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 232. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 233. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 234. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 235. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 237. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 238. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 239. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 240. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 241. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 242. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 243. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 244. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 245. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 246. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 247. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 248. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 250. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 251. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 252. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 253. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 254. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 255. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 256. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 257. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 258. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 259. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 260. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 261. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 263. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 264. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 265. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 266. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 267. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 268. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 269. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 270. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 271. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 272. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 273. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 274. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 276. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 277. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 278. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 279. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 280. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 281. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 282. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 283. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 284. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 285. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 286. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 287. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 289. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 290. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 291. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 292. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 293. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 294. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 295. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 296. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 297. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 298. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
TABLE 299. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 300. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 302. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 303. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 304. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
TABLE 305. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
TABLE 306. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
TABLE 307. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
TABLE 308. EUROPE, MIDDLE EAST & AFRICA NE
Samples
LOADING...
Companies Mentioned
The companies profiled in this Neoantigen Cancer Vaccine market report include:- Agenus Inc.
- AstraZeneca PLC
- Avidea Technologies
- Ayala Pharmaceuticals, Inc.
- BioLineRx Ltd.
- BioNTech SE
- BioVaxys Technology Corp.
- Brightpath Biotherapeutics Co., Ltd.
- CureVac N.V.
- Elicio Therapeutics Inc
- F. Hoffmann-La Roche Ltd.
- Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
- Genocea Biosciences Inc
- GenScript Biotech Corporation
- Gilead Sciences, Inc.
- Gritstone bio, Inc.
- Immunomic Therapeutics, Inc.
- ISA Pharmaceuticals B.V.
- Medigene AG
- Merck & Co., Inc.
- Moderna, Inc.
- Neophore Limited
- Nouscom AG
- Nykode Therapeutics ASA
- OSE Immunotherapeutics
- Takis S.r.l.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 196 |
| Published | May 2025 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value ( USD | $ 434.55 Million |
| Forecasted Market Value ( USD | $ 876.78 Million |
| Compound Annual Growth Rate | 15.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
